Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: April 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Podcast: Drug Fix: Leucovorin’s Resurrection, PhRMA’s Leadership Change (Listen)
- Webinar: Beyond GLP‑1s: Mapping the Next Generation of Obesity Therapeutics (2pm GMT, May 26 | Register)
- Webinar: Navigating US FDA Approval Standards for Rare Diseases: What’s Happened and What’s Next (2pm GMT, June 11 | Register)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- M&A: Sun Pharma signs Definitive Agreement to Acquire Organon for $11.75B
- M&A: Eli Lilly To Buy Kelonia For Up To $7B
- M&A: Gilead To Acquire Tubulis For Up To $5B
- Licensing: Eli Lilly, Profluent Ally In Rare Diseases totalling $2.25B
- Licensing: Regeneron Enters Radiopharm Space Through Deal with Telix totalling $2.18B ($40M upfront)
- Licensing: Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for HH160 totalling $2.02B ($20M upfront)
- Financing: Kailera Therapeutics Nets $668.4M in Initial Public Offering; Overallotment Fully Exercised
- Financing: Beeline Medicines Raises $300M in Series A Round
- Financing: Sidewinder Therapeutics Brings in $137M in Series B Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Positive: Revolution Medicines | A breakthrough for RAS-driven pancreatic cancer: daraxonrasib doubles survival versus chemotherapy
- Positive: AstraZeneca | Truqap ODAC Vote - First Targeted AKT Inhibitor Moves Closer to Prostate Cancer Approval
- Positive: CorMedix | Rezzayo (rezafungin) shows potential for antifungal prophylaxis during HSCT
- Positive: Spyre Therapeutics | Positive Phase II SKYLINE Part A induction results strengthen SPY001's potential as a best-in-class α4β7 antibody in ulcerative colitis
- Positive: NervGen | FDA alignment strengthens NervGen’s Phase 3 path for NVG-291 in chronic tetraplegia
- Negative: Compass | High crossover prevents tovecimig from achieving OS result in COMPANION-002 to send Compass stock crashing
- Negative: AstraZeneca | Strong efficacy, weak strategy: ODAC blocks camizestrant's first-line ESR1 mutation play
- Negative: Immunovant | Batoclimab misses primary endpoints in two Phase III thyroid eye disease trials
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Report: 2025 Deal-making Roundup (Link)
- Report: Gene, Cell, & RNA Therapy Landscape Q1 2026
- Report: A Guide to Patient Engagement & Recruitment Solutions
- Report: The 2026 Playbook Regulatory Leaders Can’t Afford To Miss
- Report: Q1 2026 Round Up: Proceed…With Caution
- Report: Epi & Market Forecast - Hidradenitis Suppurativa | Chronic Myeloid Leukemia
- Report: KOL Interview - Acute Lymphoblastic Leukemia | Dry Eye Syndrome | Hidradenitis Suppurativa | Idiopathic Pulmonary Fibrosis
Latest Editorial Podcasts
